Cannabis regulatory science: risk–benefit considerations for mental disorders

International Review of Psychiatry

Volumn 30, Issue 3, 2018, Pages 183-202

  Borodovsky, Jacob T ^a,b   Budney, Alan J ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

Author keywords

Cannabis; legalization; marijuana; mental disorders; psychiatric; regulatory science

Indexed keywords

ALCOHOL; CANNABIS; MEDICAL CANNABIS;

ALCOHOL CONSUMPTION; ANXIETY DISORDER; BIPOLAR DISORDER; CANNABIS USE; CLINICAL EVALUATION; DEPRESSION; DISEASE ASSOCIATION; DRUG LEGISLATION; HUMAN; LAW; LEGAL ASPECT; MENTAL DISEASE; MENTAL HEALTH; META ANALYSIS (TOPIC); NOTE; OUTCOME ASSESSMENT; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SCHIZOPHRENIA; SYSTEMATIC REVIEW (TOPIC); TOBACCO; TOBACCO USE; DRUG CONTROL;

DRUG AND NARCOTIC CONTROL; HUMANS; MEDICAL MARIJUANA; MENTAL DISORDERS; RISK ASSESSMENT;

EID: 85047801196     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.1080/09540261.2018.1454406     Document Type: Note

References (195)

1. ® (dronabinol). North Chicago, IL; AbbVie Inc. Retrieved from https://www.rxabbvie.com/pdf/marinol_PI.pdf
2. Aggarwal, S. K., Carter, G. T., Sullivan, M. D., Zumbrunnen, C., Morrill, R., & Mayer, J. D., (2013). Prospectively surveying health-related quality of life and symptom relief in a lot-based sample of medical cannabis-using patients in urban Washington State reveals managed chronic illness and debility. Am J Hosp Palliat Care, 30, 523–531. doi:10.1177/1049909112454215
3. Agosti, V., Nunes, E., & Levin, F., (2002). Rates of psychiatric comorbidity among U.S. residents with lifetime cannabis dependence. Am J Drug Alcohol Abuse, 28, 643–652. doi:10.1081/ADA-120015873
4. Agrawal, A., Nelson, E. C., Bucholz, K. K., Tillman, R., Grucza, R. A., Statham, D. J., … Lynskey, M. T., (2017). Major depressive disorder, suicidal thoughts and behaviours, and cannabis involvement in discordant twins: A retrospective cohort study. Lancet Psychiatry, 4, 706–714. doi:10.1016/S2215-0366(17)30280-8
5. Ahijevych, K., & Garrett, B. E., (2010). The role of menthol in cigarettes as a reinforcer of smoking behavior. Nicotine Tob Res, 12 Suppl 2(suppl_2), S110–S116. doi:10.1093/ntr/ntq203
6. Alexander, G. C., Gallagher, S. A., Mascola, A., Moloney, R. M., & Stafford, R. S., (2011). Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiol Drug Saf, 20, 177–184. doi:10.1002/pds.2082
7. Anderson, S. J., (2011). Marketing of menthol cigarettes and consumer perceptions: A review of tobacco industry documents. Tob Control, 20 Suppl 2(Suppl 2), ii20–ii28. doi:10.1136/tc.2010.041939
8. Apollonio, D. E., & Malone, R. E., (2005). Marketing to the marginalised: Tobacco industry targeting of the homeless and mentally ill. Tob Control, 14, 409–415. doi:10.1136/tc.2005.011890
9. ArcView Market Research. (2016). The sate of legal marijuana markets–executive summary. Retrieved from
10. Ashley, D. L., & Backinger, C. L., (2012). The food and drug administration’s regulation of tobacco: The center for tobacco products' office of science. Am J Prev Med, 43(5 Suppl 3), S255–S263. doi:10.1016/j.amepre.2012.08.004
11. Ashley, D. L., Backinger, C. L., van Bemmel, D. M., & Neveleff, D. J., (2014). Tobacco regulatory science: Research to inform regulatory action at the food and drug administration’s center for tobacco products. Nicotine Tob Res, 16, 1045–1049. doi:10.1093/ntr/ntu038
12. Babalonis, S., Haney, M., Malcolm, R. J., Lofwall, M. R., Votaw, V. R., Sparenborg, S., & Walsh, S. L., (2017). Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend, 172, 9–13. doi:10.1016/j.drugalcdep.2016.11.030
13. Bahorik, A. L., Leibowitz, A., Sterling, S. A., Travis, A., Weisner, C., & Satre, D. D., (2017). Patterns of marijuana use among psychiatry patients with depression and its impact on recovery. J Affect Disord, 213, 168–171. doi:10.1016/j.jad.2017.02.016
14. Bambico, F. R., Katz, N., Debonnel, G., & Gobbi, G., (2007). Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex. J Neurosci, 27, 11700–11711. doi:10.1523/JNEUROSCI.1636-07.2007
15. Barrus, D. G., Capogrossi, K. L., Cates, S. C., Gourdet, C. K., Peiper, N. C., Novak, S. P., … Wiley, J. L., (2016). Tasty THC: Promises and challenges of cannabis edibles. (1–17). Research Triangle Park, NC: RTI Press. Publication No. OP-0035-1611. doi:10.3768/rtipress.2016.op.0035.1611
16. Barry, R. A., & Glantz, S., (2016). A public health framework for legalized retail marijuana based on the US experience: Avoiding a new tobacco industry. PLoS Med, 13, e1002131. doi:10.1371/journal.pmed.1002131
17. Behrman, R. E., Benner, J. S., Brown, J. S., McClellan, M., Woodcock, J., & Platt, R., (2011). Developing the Sentinel system–a national resource for evidence development. N Engl J Med, 364, 498–499. doi:10.1056/NEJMp1014427
18. Belendiuk, K. A., Baldini, L. L., & Bonn-Miller, M. O., (2015). Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. Addict Sci Clin Pract, 10, 10. doi:10.1186/s13722-015-0032-7
19. Bergamaschi, M. M., Queiroz, R. H., Chagas, M. H., de Oliveira, D. C., De Martinis, B. S., Kapczinski, F., … Crippa, J. A., (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology, 36, 1219–1226. doi:10.1038/npp.2011.6
20. Bero, L., (2003). Implications of the tobacco industry documents for public health and policy. Annu Rev Public Health, 24, 267–288. doi:10.1146/annurev.publhealth.24.100901.140813
21. Bestrashniy, J., & Winters, K. C., (2015). Variability in medical marijuana laws in the United States. Psychol Addict Behav, 29, 639–642. doi:10.1037/adb0000111
22. Bierut, T., Krauss, M. J., Sowles, S. J., & Cavazos-Rehg, P. A., (2017). Exploring marijuana advertising on weedmaps, a popular online directory. Prev Sci, 18, 183–192. doi:10.1007/s11121-016-0702-z
23. Blanco, C., Hasin, D. S., Wall, M. M., Florez-Salamanca, L., Hoertel, N., Wang, S., … Olfson, M., (2016). Cannabis use and risk of psychiatric disorders: Prospective evidence from a US national longitudinal study. JAMA Psychiatry, 73, 388–395. doi:10.1001/jamapsychiatry.2015.3229
24. Boehnke, K. F., Litinas, E., & Clauw, D. J., (2016). Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain, 17, 739–744. doi:10.1016/j.jpain.2016.03.002
25. Bonn-Miller, M. O., Babson, K. A., & Vandrey, R., (2014a). Using cannabis to help you sleep: Heightened frequency of medical cannabis use among those with PTSD. Drug Alcohol Depend, 136, 162–165. doi:10.1016/j.drugalcdep.2013.12.008
26. Bonn-Miller, M. O., Boden, M. T., Bucossi, M. M., & Babson, K. A., (2014b). Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. Am J Drug Alcohol Abuse, 40, 23–30. doi:10.3109/00952990.2013.821477
27. Bonn-Miller, M. O., Boden, M. T., Vujanovic, A. A., & Drescher, K. D., (2013). Prospective investigation of the impact of cannabis use disorders on posttraumatic stress disorder symptoms among veterans in residential treatment. Psychological Trauma-Theory Research Practice and Policy, 5, 193–200. doi:10.1037/a0026621
28. Borodovsky, J. T., Crosier, B. S., Lee, D. C., Sargent, J. D., & Budney, A. J., (2016). Smoking, vaping, eating: Is legalization impacting the way people use cannabis? Int J Drug Policy, 36, 141–147. doi:10.1016/j.drugpo.2016.02.022
29. Bradford, A. C., & Bradford, W. D., (2016). Medical marijuana laws reduce prescription medication use in medicare Part D. Health Aff (Millwood), 35, 1230–1236. doi:10.1377/hlthaff.2015.1661
30. Braga, R. J., Burdick, K. E., Derosse, P., & Malhotra, A. K., (2012). Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder. Psychiatry Res, 200, 242–245. doi:10.1016/j.psychres.2012.05.025
31. Budney, A. J., & Borodovsky, J. T., (2017). The potential impact of cannabis legalization on the development of cannabis use disorders. Prev Med, 104, 31–36. doi:10.1016/j.ypmed.2017.06.034
32. Budney, A. J., Moore, B. A., Vandrey, R. G., & Hughes, J. R., (2003). The time course and significance of cannabis withdrawal. J Abnorm Psychol, 112, 393–402.10.1037/0021-843X.112.3.393
33. Campbell, C. A., Hahn, R. A., Elder, R., Brewer, R., Chattopadhyay, S., Fielding, J., … Task Force on Community Preventive, S. (2009). The effectiveness of limiting alcohol outlet density as a means of reducing excessive alcohol consumption and alcohol-related harms. Am J Prev Med, 37, 556–569. doi:10.1016/j.amepre.2009.09.028
34. Carlini, B. H., Garrett, S. B., & Harwick, R. M., (2017). Beyond joints and brownies: Marijuana concentrates in the legal landscape of WA State. Int J Drug Policy, 42, 26–29. doi:10.1016/j.drugpo.2017.01.004
35. Caulkins, J. P., (2018). Advertising restrictions on cannabis products for nonmedical use: Necessary but not sufficient? Am J Public Health, 108, 19–21. doi:10.2105/AJPH.2017.304199
36. Centers for Disease Control and Prevention (CDC). (2013). Vital signs: Current cigarette smoking among adults aged >/=18 years with mental illness–United States, 2009–2011. MMWR Morb Mortal Wkly Rep, 62, 81–87
37. Chan, G.C.K., Hall, W., Freeman, T. P., Ferris, J., Kelly, A. B., & Winstock, A., (2017). User characteristics and effect profile of Butane hash oil: An extremely high-potency cannabis concentrate. Drug Alcohol Depend, 178, 32–38. doi:10.1016/j.drugalcdep.2017.04.014
38. Chapman, S. A., Spetz, J., Lin, J., Chan, K., & Schmidt, L. A., (2016). Capturing heterogeneity in medical marijuana policies: A taxonomy of regulatory regimes across the United States. Subst Use Misuse, 51, 1174–1184. doi:10.3109/10826084.2016.1160932
39. Cheung, J. T., Mann, R. E., Ialomiteanu, A., Stoduto, G., Chan, V., Ala-Leppilampi, K., & Rehm, J., (2010). Anxiety and mood disorders and cannabis use. Am J Drug Alcohol Abuse, 36, 118–122. doi:10.3109/00952991003713784
40. Childs, E., Lutz, J. A., & de Wit, H., (2017). Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress. Drug Alcohol Depend, 177, 136–144. doi:10.1016/j.drugalcdep.2017.03.030
41. Chuang, Y. C., Cubbin, C., Ahn, D., & Winkleby, M. A., (2005). Effects of neighbourhood socioeconomic status and convenience store concentration on individual level smoking. J Epidemiol Community Health, 59, 568–573. doi:10.1136/jech.2004.029041
42. Cohn, A. M., Johnson, A. L., Hair, E., Rath, J. M., & Villanti, A. C., (2016). Menthol tobacco use is correlated with mental health symptoms in a national sample of young adults: Implications for future health risks and policy recommendations. Tob Induc Dis, 14, 1. doi:10.1186/s12971-015-0066-3
43. Cook, B. L., Wayne, G. F., Keithly, L., & Connolly, G., (2003). One size does not fit all: How the tobacco industry has altered cigarette design to target consumer groups with specific psychological and psychosocial needs. Addiction, 98, 1547–1561. doi:10.1046/j.1360-0443.2003.00563.x
44. Cooper, Z. D., & Haney, M., (2009). Actions of delta-9-tetrahydrocannabinol in cannabis: Relation to use, abuse, dependence. Int Rev Psychiatry, 21, 104–112. doi:10.1080/09540260902782752
45. Corroon, J.M., Jr., Mischley, L. K., & Sexton, M., (2017). Cannabis as a substitute for prescription drugs - a cross-sectional study. J Pain Res, 10, 989–998. doi:10.2147/JPR.S134330
46. Crippa, J. A., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., … Hallak, J. E., (2011). Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. J Psychopharmacol, 25, 121–130. doi:10.1177/0269881110379283
47. Crippa, J. A., Zuardi, A. W., Martin-Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., & Fusar-Poli, P., (2009). Cannabis and anxiety: A critical review of the evidence. Hum Psychopharmacol, 24, 515–523. doi:10.1002/hup.1048
48. D’Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y. T., … Krystal, J. H., (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology, 29, 1558–1572. doi:10.1038/sj.npp.1300496
49. Danielsson, A. K., Lundin, A., Agardh, E., Allebeck, P., & Forsell, Y., (2016). Cannabis use, depression and anxiety: A 3-year prospective population-based study. J Affect Disord, 193, 103–108. doi:10.1016/j.jad.2015.12.045
50. Daniulaityte, R., Lamy, F. R., Barratt, M., Nahhas, R. W., Martins, S. S., Boyer, E. W., … Carlson, R. G., (2017). Characterizing marijuana concentrate users: A web-based survey. Drug Alcohol Depend, 178, 399–407. doi:10.1016/j.drugalcdep.2017.05.034
51. Das, R. K., Kamboj, S. K., Ramadas, M., Yogan, K., Gupta, V., Redman, E., … Morgan, C. J., (2013). Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology (Berl), 226, 781–792. doi:10.1007/s00213-012-2955-y
52. Deep Roots Medical. (2017). Strain Guide–Blue Dream. Retrieved from http://www.deeprootsharvest.com/portfolio-item/blue-dream/ Archived: http://www.webcitation.org/6vxILTQTV
53. Degenhardt, L., Coffey, C., Romaniuk, H., Swift, W., Carlin, J. B., Hall, W. D., & Patton, G. C., (2013). The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction, 108, 124–133. doi:10.1111/j.1360-0443.2012.04015.x
54. Degenhardt, L., Hall, W., & Lynskey, M., (2001). The relationship between cannabis use, depression and anxiety among Australian adults: Findings from the national survey of mental health and well-being. Social Psychiatry and Psychiatric Epidemiology, 36, 219–227. doi: 10.1007/s001270170052
55. Dell’osso, B., & Lader, M., (2013). Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry, 28, 7–20. doi:10.1016/j.eurpsy.2011.11.003
56. Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., … Murray, R. M., (2009). High-potency cannabis and the risk of psychosis. Br J Psychiatry, 195, 488–491. doi:10.1192/bjp.bp.109.064220
57. Di Forti, M., Sallis, H., Allegri, F., Trotta, A., Ferraro, L., Stilo, S. A., … Pariante, C., (2014). Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophrenia Bulletin, 40, 1509–1517
58. Eguale, T., Buckeridge, D. L., Winslade, N. E., Benedetti, A., Hanley, J. A., & Tamblyn, R., (2012). Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch Intern Med, 172, 781–788. doi:10.1001/archinternmed.2012.340
59. ElSohly, M. A., & Gul, W., (2014). Constituents of cannabis sativa. In R., Pertwee (Ed.), Handbook of cannabis (Vol. 3, pp. 1093). Oxford: Oxford University Press
60. ElSohly, M. A., Mehmedic, Z., Foster, S., Gon, C., Chandra, S., & Church, J. C., (2016). Changes in cannabis potency over the last 2 decades (1995-2014): Analysis of current data in the United States. Biol Psychiatry, 79, 613–619. doi:10.1016/j.biopsych.2016.01.004
61. Fasinu, P. S., Phillips, S., ElSohly, M. A., & Walker, L. A., (2016). Current status and prospects for cannabidiol preparations as new therapeutic agents. Pharmacotherapy, 36, 781–796. doi:10.1002/phar.1780
62. Feingold, D., Weiser, M., Rehm, J., & Lev-Ran, S., (2015). The association between cannabis use and mood disorders: A longitudinal study. J Affect Disord, 172, 211–218. doi:10.1016/j.jad.2014.10.006
63. Feingold, D., Weiser, M., Rehm, J., & Lev-Ran, S., (2016). The association between cannabis use and anxiety disorders: Results from a population-based representative sample. Eur Neuropsychopharmacol, 26, 493–505. doi:10.1016/j.euroneuro.2015.12.037
64. First State Compassion Center. (2018). Our Products. Retrieved from http://www.firststatecompassion.com/products/ Archived at: http://www.webcitation.org/6wCOvAzUR
65. Florez-Salamanca, L., Secades-Villa, R., Hasin, D. S., Cottler, L., Wang, S., Grant, B. F., & Blanco, C., (2013). Probability and predictors of transition from abuse to dependence on alcohol, cannabis, and cocaine: Results from the national epidemiologic survey on alcohol and related conditions. Am J Drug Alcohol Abuse, 39, 168–179. doi:10.3109/00952990.2013.772618
66. Freeman, T. P., & Swift, W., (2016). Cannabis potency: The need for global monitoring. Addiction, 111, 376–377. doi:10.1111/add.13207
67. Freisthler, B., Kepple, N. J., Sims, R., & Martin, S. E., (2013). Evaluating medical marijuana dispensary policies: Spatial methods for the study of environmentally-based interventions. Am J Community Psychol, 51, 278–288. doi:10.1007/s10464-012-9542-6
68. Garden State Dispensary. (2017). Our Strains–Blackwater. Retrieved from http://www.gardenstatedispensary.com/strains/blackwater Archived at: http://www.webcitation.org/6vxE99P8u
69. Gibbs, M., Winsper, C., Marwaha, S., Gilbert, E., Broome, M., & Singh, S. P., (2015). Cannabis use and mania symptoms: A systematic review and meta-analysis. J Affect Disord, 171, 39–47. doi:10.1016/j.jad.2014.09.016
70. Gobbi, G., Bambico, F. R., Mangieri, R., Bortolato, M., Campolongo, P., Solinas, M., … Piomelli, D., (2005). Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA, 102, 18620–18625. doi:10.1073/pnas.0509591102
71. Grant, B. F., Hasin, D. S., Chou, S. P., Stinson, F. S., & Dawson, D. A., (2004). Nicotine dependence and psychiatric disorders in the United States: Results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry, 61, 1107–1115. doi:10.1001/archpsyc.61.11.1107
72. Grant, B. F., Saha, T. D., Ruan, W. J., Goldstein, R. B., Chou, S. P., Jung, J., … Hasin, D. S., (2016). Epidemiology of DSM-5 drug use disorder: Results from the national epidemiologic survey on alcohol and related conditions-III. JAMA Psychiatry, 73, 39–47. doi:10.1001/jamapsychiatry.2015.2132
73. Green, B., Young, R., & Kavanagh, D., (2005). Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry, 187, 306–313. doi:10.1192/bjp.187.4.306
74. Gururajan, A., & Malone, D. T., (2016). Does cannabidiol have a role in the treatment of schizophrenia? Schizophr Res, 176, 281–290. doi:10.1016/j.schres.2016.06.022
75. Hamilton, I., (2017). Cannabis, psychosis and schizophrenia: Unravelling a complex interaction. Addiction, 112, 1653–1657. doi:10.1111/add.13826
76. Haney, M., & Evins, A. E., (2016). Does cannabis cause, exacerbate or ameliorate psychiatric disorders? An oversimplified debate discussed. Neuropsychopharmacology, 41, 393–401. doi:10.1038/npp.2015.251
77. Hart, C. L., Ward, A. S., Haney, M., Comer, S. D., Foltin, R. W., & Fischman, M. W., (2002). Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans. Psychopharmacology (Berl), 164, 407–415. doi:10.1007/s00213-002-1231-y
78. Hasin, D. S., Kerridge, B. T., Saha, T. D., Huang, B., Pickering, R., Smith, S. M., … Grant, B. F., (2016). Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: Findings from the national epidemiologic survey on alcohol and related conditions-III. Am J Psychiatry, 173, 588–599. doi:10.1176/appi.ajp.2015.15070907
79. Haug, N. A., Kieschnick, D., Sottile, J. E., Babson, K. A., Vandrey, R., & Bonn-Miller, M. O., (2016). Training and practices of cannabis dispensary staff. Cannabis Cannabinoid Res, 1, 244–251. doi:10.1089/can.2016.0024
80. Hill, M. N., & Gorzalka, B. B., (2009). Impairments in endocannabinoid signaling and depressive illness. JAMA, 301, 1165–1166. doi:10.1001/jama.2009.369
81. Hirshbein, L., (2012). Scientific research and corporate influence: Smoking, mental illness, and the tobacco industry. J Hist Med Allied Sci, 67, 374–397. doi:10.1093/jhmas/jrr019
82. Hoffman, K. A., Terashima, J. P., McCarty, D., & Muench, J., (2017). Toward a patient registry for cannabis use: An exploratory study of patient use in an outpatient health-care clinic in oregon. World Med Health Policy, 9, 307–317. doi:10.1002/wmh3.237
83. Hunault, C. C., Bocker, K. B., Stellato, R. K., Kenemans, J. L., de Vries, I., & Meulenbelt, J., (2014). Acute subjective effects after smoking joints containing up to 69 mg Delta9-tetrahydrocannabinol in recreational users: A randomized, crossover clinical trial. Psychopharmacology (Berl), 231, 4723–4733. doi:10.1007/s00213-014-3630-2
84. Hurt, R. D., & Robertson, C. R., (1998). Prying open the door to the tobacco industry’s secrets about nicotine: The minnesota tobacco trial. JAMA, 280, 1173–1181
85. Jahiel, R. I., & Babor, T. F., (2007). Industrial epidemics, public health advocacy and the alcohol industry: Lessons from other fields. Addiction, 102, 1335–1339. doi:10.1111/j.1360-0443.2007.01900.x
86. Jane-Llopis, E., & Matytsina, I., (2006). Mental health and alcohol, drugs and tobacco: A review of the comorbidity between mental disorders and the use of alcohol, tobacco and illicit drugs. Drug Alcohol Rev, 25, 515–536. doi:10.1080/09595230600944461
87. Jason, L. A., Ji, P. Y., Anes, M. D., & Birkhead, S. H., (1991). Active enforcement of cigarette control laws in the prevention of cigarette sales to minors. JAMA, 266, 3159–3161. doi:10.1001/jama.1991.03470220075030
88. Jetly, R., Heber, A., Fraser, G., & Boisvert, D., (2015). The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology, 51, 585–588. doi:10.1016/j.psyneuen.2014.11.002
89. Karschner, E. L., Darwin, W. D., McMahon, R. P., Liu, F., Wright, S., Goodwin, R. S., & Huestis, M. A., (2011). Subjective and physiological effects after controlled Sativex and oral THC administration. Clin Pharmacol Ther, 89, 400–407. doi:10.1038/clpt.2010.318
90. Keller, C. J., Chen, E. C., Brodsky, K., & Yoon, J. H., (2016). A case of butane hash oil (marijuana wax)-induced psychosis. Subst Abus, 37, 384–386. doi:10.1080/08897077.2016.1141153
91. Kesselheim, A. S., Mello, M. M., & Studdert, D. M., (2011). Strategies and practices in off-label marketing of pharmaceuticals: A retrospective analysis of whistleblower complaints. PLoS Med, 8, e1000431. doi:10.1371/journal.pmed.1000431
92. Kessler, R. C., (2004). The epidemiology of dual diagnosis. Biol Psychiatry, 56, 730–737. doi:10.1016/j.biopsych.2004.06.034
93. Khantzian, E. J., (1997). The self-medication hypothesis of substance use disorders: A reconsideration and recent applications. Harv Rev Psychiatry, 4, 231–244. doi:10.3109/10673229709030550
94. Kilmer, B., & Pacula, R. L., (2017a). Building the data infrastructure to evaluate cannabis legalization. Addiction, 112, 1140–1141. doi:10.1111/add.13824
95. Kilmer, B., & Pacula, R. L., (2017b). Understanding and learning from the diversification of cannabis supply laws. Addiction, 112, 1128–1135. doi:10.1111/add.13623
96. Kim, S. W., Dodd, S., Berk, L., Kulkarni, J., de Castella, A., Fitzgerald, P. B., … Berk, M., (2015). Impact of Cannabis use on long-term remission in bipolar I and schizoaffective disorder. Psychiatry Investig, 12, 349–355. doi:10.4306/pi.2015.12.3.349
97. Kirk, J. M., & De Wit, H., (1999). Responses to oral Δ9-tetrahydrocannabinol in frequent and infrequent marijuana users. Pharmacology Biochemistry and Behavior, 63, 137–142. doi:10.1016/s0091-3057(98)00264-0
98. Lagerberg, T. V., Kvitland, L. R., Aminoff, S. R., Aas, M., Ringen, P. A., Andreassen, O. A., & Melle, I., (2014). Indications of a dose-response relationship between cannabis use and age at onset in bipolar disorder. Psychiatry Res, 215, 101–104. doi:10.1016/j.psychres.2013.10.029
99. Lankenau, S. E., Ataiants, J., Mohanty, S., Schrager, S., Iverson, E., & Wong, C. F., (2018). Health conditions and motivations for marijuana use among young adult medical marijuana patients and non-patient marijuana users. Drug Alcohol Rev, 37, 237–246. doi:10.1111/dar.12534
100. Lasser, K., Boyd, J. W., Woolhandler, S., Himmelstein, D. U., McCormick, D., & Bor, D. H., (2000). Smoking and mental illness: A population-based prevalence study. JAMA, 284, 2606–2610.10.1001/jama.284.20.2606
101. Le Foll, B., Gorelick, D. A., & Goldberg, S. R., (2009). The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl), 205, 171–174. doi:10.1007/s00213-009-1506-7
102. Lenton, S., & Subritzky, T., (2017). On sentinel samples, sales data and potency. Addiction, 112, 1137–1138. doi:10.1111/add.13756
103. Lev-Ran, S., Imtiaz, S., Rehm, J., & Le Foll, B., (2013). Exploring the association between lifetime prevalence of mental illness and transition from substance use to substance use disorders: Results from the National Epidemiologic Survey of Alcohol and Related Conditions (NESARC). Am J Addict, 22, 93–98. doi:10.1111/j.1521-0391.2013.00304.x
104. Lev-Ran, S., Le Foll, B., McKenzie, K., George, T. P., & Rehm, J., (2013). Cannabis use and cannabis use disorders among individuals with mental illness. Compr Psychiatry, 54, 589–598. doi:10.1016/j.comppsych.2012.12.021
105. Lev-Ran, S., Roerecke, M., Le Foll, B., George, T. P., McKenzie, K., & Rehm, J., (2014). The association between cannabis use and depression: A systematic review and meta-analysis of longitudinal studies. Psychol Med, 44, 797–810. doi:10.1017/S0033291713001438
106. Levy, D. T., Blackman, K., Tauras, J., Chaloupka, F. J., Villanti, A. C., Niaura, R. S., … Abrams, D. B., (2011). Quit attempts and quit rates among menthol and nonmenthol smokers in the United States. Am J Public Health, 101, 1241–1247. doi:10.2105/AJPH.2011.300178
107. Levy, S., & Weitzman, E. R., (2016). Building a learning marijuana surveillance system. JAMA Pediatr, 170, 193–194. doi:10.1001/jamapediatrics.2015.3489
108. Leweke, F. M., Mueller, J. K., Lange, B., & Rohleder, C., (2016). Therapeutic potential of cannabinoids in psychosis. Biol Psychiatry, 79, 604–612. doi:10.1016/j.biopsych.2015.11.018
109. Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., … Koethe, D., (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry, 2, e94. doi:10.1038/tp.2012.15
110. Lewis, M. A., Backes, M. D., & Giese, M., (2015). U.S. Patent and Trademark Office
111. Loflin, M., & Earleywine, M., (2014). A new method of cannabis ingestion: The dangers of dabs? Addict Behav, 39, 1430–1433. doi:10.1016/j.addbeh.2014.05.013
112. Loflin, M. J., Babson, K. A., & Bonn-Miller, M. O., (2017). Cannabinoids as therapeutic for PTSD. Curr Opin Psychol, 14, 78–83. doi:10.1016/j.copsyc.2016.12.001
113. Lopez-Quintero, C., Perez de los Cobos, J., Hasin, D. S., Okuda, M., Wang, S., Grant, B. F., & Blanco, C., (2011). Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: Results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend, 115, 120–130. doi:10.1016/j.drugalcdep.2010.11.004
114. Lucas, P., & Walsh, Z., (2017). Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. Int J Drug Policy, 42, 30–35. doi:10.1016/j.drugpo.2017.01.011
115. Lucas, P., Walsh, Z., Crosby, K., Callaway, R., Belle-Isle, L., Kay, R., … Holtzman, S., (2016). Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors. Drug Alcohol Rev, 35, 326–333. doi:10.1111/dar.12323
116. Mack, A., (2003). Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm, 9, 559–568. doi:10.18553/jmcp.2003.9.6.559
117. Mair, C., Freisthler, B., Ponicki, W. R., & Gaidus, A., (2015). The impacts of marijuana dispensary density and neighborhood ecology on marijuana abuse and dependence. Drug Alcohol Depend, 154, 111–116. doi:10.1016/j.drugalcdep.2015.06.019
118. Martin-Santos, R., Crippa, J. A., Batalla, A., Bhattacharyya, S., Atakan, Z., Borgwardt, S., … McGuire, P. K., (2012). Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des, 18, 4966–4979
119. Martins, S. S., & Gorelick, D. A., (2011). Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the U.S. population. Drug Alcohol Depend, 119, 28–36. doi:10.1016/j.drugalcdep.2011.05.010
120. McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., … Wright, S., (2018). Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. Am J Psychiatry, 175, 225–231. doi:10.1176/appi.ajp.2017.17030325
121. McKean, A., & Monasterio, E., (2012). Off-label use of atypical antipsychotics: Cause for concern? CNS Drugs, 26, 383–390. doi:10.2165/11632030-000000000-00000
122. Mechoulam, R., & Parker, L. A., (2013). The endocannabinoid system and the brain. Annu Rev Psychol, 64, (21–47. doi:10.1146/annurev-psych-113011-143739
123. Meier, P. S., Purshouse, R., & Brennan, A., (2010). Policy options for alcohol price regulation: The importance of modelling population heterogeneity. Addiction, 105, 383–393. doi:10.1111/j.1360-0443.2009.02721.x
124. Mello, M. M., Studdert, D. M., & Brennan, T. A., (2009). Shifting terrain in the regulation of off-label promotion of pharmaceuticals. N Engl J Med, 360, 1557–1566. doi:10.1056/NEJMhle0807695
125. Micale, V., Di Marzo, V., Sulcova, A., Wotjak, C. T., & Drago, F., (2013). Endocannabinoid system and mood disorders: Priming a target for new therapies. Pharmacol Ther, 138, 18–37. doi:10.1016/j.pharmthera.2012.12.002
126. Moncrieff, J., (2011). Co-opting psychiatry: The alliance between academic psychiatry and the pharmaceutical industry. Epidemiology and Psychiatric Sciences, 16, 192–196. doi:https://doi.org/10.1017/S1121189X00002268
127. Moncrieff, J., Hopker, S., & Thomas, P., (2018). Psychiatry and the pharmaceutical industry: Who pays the piper? Psychiatric Bulletin, 29, 84–85. doi:10.1192/pb.29.3.84
128. Morrison, C., Gruenewald, P. J., Freisthler, B., Ponicki, W. R., & Remer, L. G., (2014). The economic geography of medical cannabis dispensaries in California. Int J Drug Policy, 25, 508–515. doi:10.1016/j.drugpo.2013.12.009
129. National Academies of Sciences Engineering Medicine. (2017). The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, DC: The National Academies Press
130. Nemeth, J., & Ross, E., (2014). Planning for marijuana the cannabis conundrum. Journal of the American Planning Association, 80, 6–20. doi:10.1080/01944363.2014.935241
131. Nunberg, H., Kilmer, B., Pacula, R. L., & Burgdorf, J., (2011). An analysis of applicants presenting to a medical marijuana specialty practice in California. J Drug Policy Anal, 4, 1–16. doi:10.2202/1941-2851.1017
132. O'Neil, M. E., Nugent, S. M., Morasco, B. J., Freeman, M., Low, A., Kondo, K., … Kansagara, D., (2017). Benefits and harms of plant-based cannabis for posttraumatic stress disorder: A systematic review. Ann Intern Med, 167, 332–340. doi:10.7326/M17-0477
133. Pacula, R. L., Hunt, P., & Boustead, A., (2014). Words can be deceiving: A review of variation among legally effective medical marijuana laws in the United States. J Drug Policy Anal, 7, 1–19. doi:10.1515/jdpa-2014-0001
134. Pacula, R. L., Kilmer, B., Wagenaar, A. C., Chaloupka, F. J., & Caulkins, J. P., (2014). Developing public health regulations for marijuana: Lessons from alcohol and tobacco. Am J Public Health, 104, 1021–1028. doi:10.2105/AJPH.2013.301766
135. Pacula, R. L., Powell, D., Heaton, P., & Sevigny, E. L., (2015). Assessing the effects of medical marijuana laws on marijuana use: The devil is in the details. J Policy Anal Manage, 34, 7–31.10.1002/pam.21804
136. Papini, S., Ruglass, L. M., Lopez-Castro, T., Powers, M. B., Smits, J. A., & Hien, D. A., (2017). Chronic cannabis use is associated with impaired fear extinction in humans. J Abnorm Psychol, 126, 117–124. doi:10.1037/abn0000224
137. Pearson, A. L., Bowie, C., & Thornton, L. E., (2014). Is access to alcohol associated with alcohol/substance abuse among people diagnosed with anxiety/mood disorder? Public Health, 128, 968–976. doi:10.1016/j.puhe.2014.07.008
138. Peiper, N. C., Baumgartner, P. M., Chew, R. F., Hsieh, Y. P., Bieler, G. S., Bobashev, G. V., … Zarkin, G. A., (2017). Patterns of Twitter behavior among networks of cannabis dispensaries in California. J Med Internet Res, 19, e236. doi:10.2196/jmir.7137
139. Pereira, G., Wood, L., Foster, S., & Haggar, F., (2013). Access to alcohol outlets, alcohol consumption and mental health. PLoS One, 8, e53461. doi: 10.1371/journal.pone.0053461
140. Perese, E. F., (2016). Stigma, poverty, and victimization: Roadblocks to recovery for individuals with severe mental illness. Journal of the American Psychiatric Nurses Association, 13, 285–295. doi:10.1177/1078390307307830
141. Pierre, J. M., Gandal, M., & Son, M., (2016). Cannabis-induced psychosis associated with high potency “wax dabs”. Schizophr Res, 172, 211–212. doi:10.1016/j.schres.2016.01.056
142. Piper, B. J., DeKeuster, R. M., Beals, M. L., Cobb, C. M., Burchman, C. A., Perkinson, L., … Abess, A. T., (2017). Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J Psychopharmacol, 31, 569–575. doi:10.1177/0269881117699616
143. Prochaska, J. J., Das, S., & Young-Wolff, K. C., (2017). Smoking, mental illness, and public health. Annu Rev Public Health, 38, 165–185. doi:10.1146/annurev-publhealth-031816-044618
144. Prochaska, J. J., Hall, S. M., & Bero, L. A., (2008). Tobacco use among individuals with schizophrenia: What role has the tobacco industry played? Schizophr Bull, 34, 555–567. doi:10.1093/schbul/sbm117
145. Rabin, R. A., & George, T. P., (2017). Understanding the link between cannabinoids and psychosis. Clin Pharmacol Ther, 101, 197–199. doi:10.1002/cpt.421
146. Rabin, R. A., Zakzanis, K. K., & George, T. P., (2011). The effects of cannabis use on neurocognition in schizophrenia: A meta-analysis. Schizophr Res, 128, 111–116. doi:10.1016/j.schres.2011.02.017
147. Rabinak, C. A., Angstadt, M., Sripada, C. S., Abelson, J. L., Liberzon, I., Milad, M. R., & Phan, K. L., (2013). Cannabinoid facilitation of fear extinction memory recall in humans. Neuropharmacology, 64, 396–402. doi:10.1016/j.neuropharm.2012.06.063
148. Radhakrishnan, R., Wilkinson, S. T., & D’Souza, D. C., (2014). Gone to pot–A review of the association between cannabis and psychosis. Front Psychiatry, 5, 54. doi:10.3389/fpsyt.2014.00054
149. Reiman, A., (2016). Medical cannabis patients: Patient profiles and health care utilization patterns. Complementary Health Practice Review, 12, 31–50. doi:10.1177/1533210107301834
150. Reinarman, C., Nunberg, H., Lanthier, F., & Heddleston, T., (2011). Who are medical marijuana patients? Population characteristics from nine California assessment clinics. J Psychoactive Drugs, 43, 128–135. doi:10.1080/02791072.2011.587700
151. Reitzel, L. R., Cromley, E. K., Li, Y., Cao, Y., Dela Mater, R., Mazas, C. A., … Wetter, D. W., (2011). The effect of tobacco outlet density and proximity on smoking cessation. Am J Public Health, 101, 315–320. doi:10.2105/AJPH.2010.191676
152. Richter, K. P., & Levy, S., (2014). Big marijuana-lessons from big tobacco. N Engl J Med, 371, 399–401. doi:10.1056/NEJMp1406074
153. Roitman, P., Mechoulam, R., Cooper-Kazaz, R., & Shalev, A., (2014). Preliminary, open-label, pilot study of add-on oral Delta9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig, 34, 587–591. doi:10.1007/s40261-014-0212-3
154. Russo, E. B., (2011). Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol, 163, 1344–1364. doi:10.1111/j.1476-5381.2011.01238.x
155. Sagar, K. A., Dahlgren, M. K., Racine, M. T., Dreman, M. W., Olson, D. P., & Gruber, S. A., (2016). Joint effects: A pilot investigation of the impact of bipolar disorder and marijuana use on cognitive function and mood. PLoS One, 11, e0157060. doi:10.1371/journal.pone.0157060
156. Sanctuary Alternative Treatment Center. (2017). Product Menu. Retrieved from http://www.sanctuaryatc.org/NH-menu.php Archived at: http://www.webcitation.org/6w3BLVGdF
157. Schlienz, N. J., Budney, A. J., Lee, D. C., & Vandrey, R., (2017). Cannabis withdrawal: A review of neurobiological mechanisms and sex differences. Curr Addict Rep, 4, 75–81. doi:10.1007/s40429-017-0143-1
158. Schoeler, T., Monk, A., Sami, M. B., Klamerus, E., Foglia, E., Brown, R., … Bhattacharyya, S., (2016). Continued versus discontinued cannabis use in patients with psychosis: A systematic review and meta-analysis. Lancet Psychiatry, 3, 215–225. doi:10.1016/S2215-0366(15)00363-6
159. Segev, A., & Lev-Ran, S., (2012). Neurocognitive functioning and cannabis use in schizophrenia. Curr Pharm Des, 18, 4999–5007. doi: 10.2174/138161212802884799
160. Sexton, M., Cuttler, C., Finnell, J. S., & Mischley, L. K., (2016). A cross-sectional survey of medical cannabis users: Patterns of use and perceived efficacy. Cannabis Cannabinoid Res, 1, 131–138. doi:10.1089/can.2016.0007
161. Shi, Y., Meseck, K., & Jankowska, M. M., (2016). Availability of medical and recreational marijuana stores and neighborhood characteristics in Colorado. J Addict, 2016, 7193740. doi:10.1155/2016/7193740
162. Stafford, R. S., (2008). Regulating off-label drug use-rethinking the role of the FDA. N Engl J Med, 358, 1427–1429. doi:10.1056/NEJMp0802107
163. Stinson, F. S., Ruan, W. J., Pickering, R., & Grant, B. F., (2006). Cannabis use disorders in the USA: Prevalence, correlates and co-morbidity. Psychol Med, 36, 1447–1460. doi:10.1017/S0033291706008361
164. Subritzky, T., Lenton, S., & Pettigrew, S., (2016). Legal cannabis industry adopting strategies of the tobacco industry. Drug Alcohol Rev, 35, 511–513. doi:10.1111/dar.12459
165. Subritzky, T., Pettigrew, S., & Lenton, S., (2015). Issues in the implementation and evolution of the commercial recreational cannabis market in Colorado. Int J Drug Policy, 27, 1–12. doi:10.1016/j.drugpo.2015.12.001
166. Summit Medical Compassion Center. (2017). Medical Cannabis Menu - Vancouver Island Haze. Retrieved from http://www.summitri.org/menu/ Archived at: http://www.webcitation.org/6vxHvOHZ0
167. Teesson, M., Slade, T., Swift, W., Mills, K., Memedovic, S., Mewton, L., … Hall, W., (2012). Prevalence, correlates and comorbidity of DSM-IV cannabis use and cannabis use disorders in Australia. Aust N Z J Psychiatry, 46, 1182–1192. doi:10.1177/0004867412460591
168. The Clinic Marijuana Center. (2017). The Clinic Strain Book. Retrieved from http://www.thecliniccolorado.com/strain-book/ Archived at: http://www.webcitation.org/6vrUFdPCp
169. Thomas, C., & Freisthler, B., (2016). Examining the locations of medical marijuana dispensaries in Los Angeles. Drug Alcohol Rev, 35, 334–337. doi:10.1111/dar.12325
170. Throckmorton, D. C., (2016). Researching the potential medical benefits and risks of marijuana. Retrieved from https://www.fda.gov/NewsEvents/Testimony/ucm511057.htm
171. Troutt, W. D., & DiDonato, M. D., (2015). Medical Cannabis in Arizona: Patient Characteristics, Perceptions, and Impressions of Medical Cannabis Legalization. J Psychoactive Drugs, 47, 259–266. doi:10.1080/02791072.2015.1074766
172. U.S. Food and Drug Administration. (2016). 2016 Warning letters and test results for cannabidiol-related products. Retrieved from http://www.fda.gov/NewsEvents/PublicHealthFocus/ucm484109.htm
173. U.S. Food and Drug Administration. (2018). FDA’s sentinel initiative–background. Retrieved from https://www.fda.gov/Safety/FDAsSentinelInitiative/ucm149340.htm Archived at: http://www.webcitation.org/6wCf9YVxa
174. Ugwu, R., (2017). Veterans groups push for medical marijuana to treat PTSD. The New York Times
175. van Laar, M., van Dorsselaer, S., Monshouwer, K., & de Graaf, R., (2007). Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population? Addiction, 102, 1251–1260. doi:10.1111/j.1360-0443.2007.01875.x
176. van Ours, J. C., (2017). Data on cannabis use now that legalization is gaining momentum. Addiction, 112, 1138–1140. doi:10.1111/add.13769
177. van Rossum, I., Boomsma, M., Tenback, D., Reed, C., & van Os, J., (2009). Does cannabis use affect treatment outcome in bipolar disorder?: A longitudinal analysis. The Journal of Nervous and Mental Disease, 197, 35–40. doi:10.1097/NMD.0b013e31819292a6
178. Vandrey, R., Herrmann, E. S., Mitchell, J. M., Bigelow, G. E., Flegel, R., LoDico, C., & Cone, E. J., (2017). Pharmacokinetic profile of oral cannabis in humans: Blood and oral fluid disposition and relation to pharmacodynamic outcomes. J Anal Toxicol, 41, 83–99. doi:10.1093/jat/bkx012
179. Vedula, S. S., Bero, L., Scherer, R. W., & Dickersin, K., (2009). Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med, 361, 1963–1971. doi:10.1056/NEJMsa0906126
180. Villanti, A. C., Vargyas, E. J., Niaura, R. S., Beck, S. E., Pearson, J. L., & Abrams, D. B., (2011). Food and drug administration regulation of tobacco: Integrating science, law, policy, and advocacy. Am J Public Health, 101, 1160–1162. doi:10.2105/AJPH.2011.300229
181. Wagenaar, A. C., Toomey, T. L., & Erickson, D. J., (2005). Preventing youth access to alcohol: Outcomes from a multi-community time-series trial*. Addiction, 100, 335–345. doi:10.1111/j.1360-0443.2005.00973.x
182. Walsh, Z., Callaway, R., Belle-Isle, L., Capler, R., Kay, R., Lucas, P., & Holtzman, S., (2013). Cannabis for therapeutic purposes: Patient characteristics, access, and reasons for use. Int J Drug Policy, 24, 511–516. doi:10.1016/j.drugpo.2013.08.010
183. Walsh, Z., Gonzalez, R., Crosby, K., S Thiessen, M., Carroll, C., & Bonn-Miller, M. O., (2017). Medical cannabis and mental health: A guided systematic review. Clin Psychol Rev, 51, 15–29. doi:10.1016/j.cpr.2016.10.002
184. Wang, G. S., Le Lait, M. C., Deakyne, S. J., Bronstein, A. C., Bajaj, L., & Roosevelt, G., (2016). Unintentional pediatric exposures to marijuana in Colorado, 2009–2015. JAMA Pediatr, 170, e160971. doi:10.1001/jamapediatrics.2016.0971
185. Wang, P. S., Lane, M., Olfson, M., Pincus, H. A., Wells, K. B., & Kessler, R. C., (2005). Twelve-month use of mental health services in the United States: Results from the national comorbidity survey replication. Arch Gen Psychiatry, 62, 629–640. doi:10.1001/archpsyc.62.6.629
186. Ware, M. A., Martel, M. O., Jovey, R., Lynch, M. E., & Singer, J., (2018). A prospective observational study of problematic oral cannabinoid use. Psychopharmacology (Berl), 235, 409–417. doi:10.1007/s00213-017-4811-6
187. Weed, J., (2017). US patent office issuing cannabis patents to a growing market. Retrieved from https://www.forbes.com/sites/julieweed/2017/07/24/us-patent-office-issuing-cannabis-patents-to-a-growing-market/#7e5d1ae68d40 Archived at: http://www.webcitation.org/6w6IDFmUO
188. Weiss, S.R.B., Howlett, K. D., & Baler, R. D., (2017). Building smart cannabis policy from the science up. Int J Drug Policy, 42, 39–49. doi:10.1016/j.drugpo.2017.01.007
189. Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., … Kleijnen, J., (2015). Cannabinoids for medical use: A systematic review and meta-analysis. JAMA, 313, 2456–2473. doi:10.1001/jama.2015.6358
190. Wilkinson, S. T., Stefanovics, E., & Rosenheck, R. A., (2015). Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry, 76, 1174–1180. doi:10.4088/JCP.14m09475
191. Williams, A. R., Olfson, M., Kim, J. H., Martins, S. S., & Kleber, H. D., (2016). Older, less regulated medical marijuana programs have much greater enrollment rates than newer 'Medicalized' programs. Health Aff (Millwood), 35, 480–488. doi:10.1377/hlthaff.2015.0528
192. Young-Wolff, K. C., Henriksen, L., Delucchi, K., & Prochaska, J. J., (2014). Tobacco retailer proximity and density and nicotine dependence among smokers with serious mental illness. Am J Public Health, 104, 1454–1463. doi:10.2105/AJPH.2014.301917
193. Zorrilla, I., Aguado, J., Haro, J., Barbeito, S., López Zurbano, S., Ortiz, A., … Gonzalez-Pinto, A., (2015). Cannabis and bipolar disorder: Does quitting cannabis use during manic/mixed episode improve clinical/functional outcomes? Acta Psychiatrica Scandinavica, 131, 100–110
194. Zuardi, A., Crippa, J., Dursun, S., Morais, S., Vilela, J., Sanches, R., & Hallak, J., (2010). Cannabidiol was ineffective for manic episode of bipolar affective disorder. J Psychopharmacol, 24, 135–137. doi:10.1177/0269881108096521
195. Zvolensky, M. J., Cougle, J. R., Johnson, K. A., Bonn-Miller, M. O., & Bernstein, A., (2010). Marijuana use and panic psychopathology among a representative sample of adults. Exp Clin Psychopharmacol, 18, 129–134. doi:10.1037/a0019022